Scheibenbogen:
Die Entfernung von Autoantikörpern mit Immunadsoprtion kann auch bei #MECFS nach COVID #PCS zu rascher Besserung führen. Erste Ergebnisse unserer #NKSG Studie als preprint, gefördert durch #BMBF von Autoantikörpern mit Immunadsoprtion kann auch bei #MECFS nach COVID #PCS zu rascher Besserung führen. Erste Ergebnisse unserer #NKSG Studie als preprint, gefördert durch #BMBF
t.co/na337oAT2J

RT @vaccelerate_eu: Special #VACCELERATE #COVID19 #LongCovid #PostCovid #clinicaltrials webinar: April 26 2023.
With @C_Scheibenbogen @ChariteBerlin #NKSG. Moderated by @Prof_Schmitt. Participation is free of charge. Registration: https://uni-koeln.zoom.us/meeting/register/tJ0kdOCqpjktHtPLZgYzjjaQpF9GMQByoGnA
@EU_HaDEA @UniCologne @CECAD_ @UKKoeln

🐦🔗: https://n.respublicae.eu/EU_HaDEA/status/1646121391769411585

Welcome! You are invited to join a meeting: VACCELERATE Webinar: Clinical Trials on Chronic Fatigue Syndrome and Post-COVID Syndrome. After registering, you will receive a confirmation email about joining the meeting.

Clinical Trials on Chronic Fatigue Syndrome (ME/CFS) and Post-COVID Syndrome With Prof. Carmen Scheibenbogen, Charité Berlin, Germany The Post-COVID Syndrome (PCS) can vary greatly in severity, but is usually accompanied by severe fatigue. Some of those affected suffer from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Knowledge about targeted therapies for both conditions is still in its infancy. Little is known about the exact disease mechanisms of ME/CFS and Post-COVID syndrome. Therefore, no targeted medical treatments exist. As a result, many people with ME/CFS are perpetually ill and unable to work or to take care of their families. Researchers at Charité - Universitätsmedizin Berlin have now founded a National Clinical Study Group to conduct the first clinical trials with drugs for the treatment of PCS and ME/CFS. Prof. Scheibenbogen's study group wants to initiate and conduct first clinical trials with drugs and medical procedures for PCS and ME/CFS. The aim is to receive approval for effective therapies to make them available to all patients. The focus is on drugs that are already available for other diseases to achieve rapid progress in treatment. In this webinar, Prof. Scheibenbogen introduces the study group and its goals. She will explain how the process of enrolling patients and conducting the studies is planned and when first results can be expected.

Zoom

DAS sind die, in die betroffene von #LongCovid u/o #MECFS ihre hoffnungen setzen 🦠💦🤪

"Heute besuchte uns Katrin @GoeringEckardt an der @ChariteBerlin um sich beim Team der #NKSG über die Forschung und klinischen Studien zu #MECFS und #PCS zu informieren. Vielen Dank für das große Engagement und die Unterstützung."

#Corona #Eigenverantwortung #Covid #Maskenpflicht #EuthanasieViaVirus #Infektionsschutz #TeamWissenschaftAmLimit #scheibenbogen #DavosStandard ? #Vulnerable